Association of glucagon-like peptide-1 receptor agonists with acute pancreatitis and biliary disease in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study.
糖尿病和肥胖患者中，胰高血糖素樣肽-1受體激動劑與急性胰腺炎和膽道疾病的關聯：一項傾向加權的基於人群的隊列研究。
Gac Sanit 2025-01-16
Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study.
糖尿病和肥胖患者中，胰高血糖素樣肽-1受體激動劑與自殺意念和自我傷害的關聯：一項傾向加權的基於人群的隊列研究。
Diabetologia 2024-08-05
The incidence of acute pancreatitis with GLP-1 receptor agonist therapy in individuals with a known history of pancreatitis.
已知有胰臟炎病史的個體在接受 GLP-1 受體激動劑治療時急性胰臟炎的發生率。
Diabetes Res Clin Pract 2024-08-07
Association between glucagon-like peptide-1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database.
胰高血糖素樣肽-1 受體激動劑與自殺風險之間的關聯：全球藥物監測數據庫的綜合分析。
Diabetes Obes Metab 2024-08-20
Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study.
肥胖且無第二型糖尿病個體中，胰高血糖素樣肽-1受體激動劑的長期安全性和療效：一項全球回顧性隊列研究。
Diabetes Obes Metab 2024-08-22
The potential adverse effects of hypodermic glucagon-like peptide -1 receptor agonist on patients with type 2 diabetes: A population-based study.
對2型糖尿病患者使用皮下注射的胰高血糖素樣肽-1受體激動劑的潛在不良影響：一項基於人群的研究。
J Diabetes 2024-10-22
Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis.
不同 GLP-1 受體激動劑與急性胰臟炎的關聯：病例系列及實際世界藥物監測分析。
Front Pharmacol 2024-11-28
胰高血糖素樣肽-1 受體激動劑（GLP-1 RAs）雖然能改善血糖管理，但關於其引發急性胰臟炎（AP）的風險資料仍然不足。本研究分析了多種 GLP-1 RAs（如 exenatide、lixisenatide、liraglutide 等）與 AP 風險的關聯，透過公共不良事件數據庫和病例報告進行。研究涵蓋了39名使用 GLP-1 RAs 的 AP 患者，並檢索了2005年至2023年的FDA不良事件報告。結果顯示所有 GLP-1 RAs 都有顯著的 AP 報告信號，特別是 exenatide 和 liraglutide，提醒醫療人員需密切監控此嚴重不良事件。
PubMedDOI
The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study.
在2型糖尿病患者中，GLP-1 受體激動劑與臨床相關膽結石的相對風險，實際世界研究。
Diabetol Metab Syndr 2024-12-05
Gastrointestinal Safety Assessment of GLP-1 Receptor Agonists in the US: A Real-World Adverse Events Analysis from the FAERS Database.
美國 GLP-1 受體激動劑的胃腸安全性評估：來自 FAERS 數據庫的真實世界不良事件分析。
Diagnostics (Basel) 2025-01-08
Unexpected cardiovascular risks of glucagon-like peptide-1 receptor agonist and aspirin co-administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study.
肥胖者中GLP-1受體激動劑與阿斯匹靈聯合使用的意外心血管風險：一項傾向得分匹配的隊列研究，無論是否患有2型糖尿病。
Diabetes Obes Metab 2025-01-14